Quarterly ResultJul 30, 2026, 04:51 PM
Baxter Q2 Net Sales $2.96B, Net Income $126M; H1 Operating Cash Flow Up
AI Summary
Baxter International reported increased net sales and operating income for the second quarter of 2026. Net sales rose to $2.96 billion, with net income attributable to stockholders reaching $126 million. For the first half of 2026, cash flow from continuing operations significantly improved to $510 million. The company also noted ongoing legal proceedings related to its Novum LVP product and a reduced quarterly dividend.
Key Highlights
- Q2 2026 net sales increased to $2.96 billion from $2.81 billion in Q2 2025.
- Q2 2026 net income attributable to stockholders rose to $126 million from $91 million in Q2 2025.
- Diluted EPS for Q2 2026 was $0.24, up from $0.18 in Q2 2025.
- Cash flows from continuing operations for H1 2026 were $510 million, up from $118 million in H1 2025.
- Long-term debt decreased to $8.62 billion as of June 30, 2026, from $9.47 billion at year-end 2025.
- Quarterly cash dividend declared was $0.01 per share, down from $0.17 per share in Q2 2025.
- Pharmaceuticals segment goodwill reallocated into Medical Products & Therapies segment.
- Company faces ongoing legal proceedings and Class I recalls for Novum LVP.
Price Impact
More from BAX